Patents by Inventor Koen Kas

Koen Kas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8697370
    Abstract: Methods for the diagnosis, prognosis and prediction of sepsis in a subject using the expression levels of the biomarkers Triggering Receptor Expressed on Myeloid cells-1 (TREM-1) and TREM-like receptor transcript-1 (TLT1) as an indication of the condition of the patient, alone or in combination with further sepsis markers are disclosed. If the levels of the biomarkers indicate the presence of sepsis, the patient is treated for sepsis with an antibiotic and/or fluid resuscitation treatment.
    Type: Grant
    Filed: May 19, 2009
    Date of Patent: April 15, 2014
    Assignee: Pronota N.V.
    Inventors: Koen Kas, Griet Vanpoucke
  • Patent number: 8628979
    Abstract: The application discloses MCAM as a new biomarker for fluid homeostatic imbalance; methods for predicting, diagnosing, prognosticating and/or monitoring fluid homeostatic imbalance based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods.
    Type: Grant
    Filed: October 21, 2010
    Date of Patent: January 14, 2014
    Assignee: Pronota N.V.
    Inventor: Koen Kas
  • Patent number: 8501418
    Abstract: The application discloses PERLECAN as a new biomarker for renal dysfunction; methods for predicting, diagnosing, prognosticating and/or monitoring said dysfunction based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods.
    Type: Grant
    Filed: August 5, 2011
    Date of Patent: August 6, 2013
    Assignee: Pronata N.V.
    Inventors: Koen Kas, Griet Vanpoucke, Piet Moerman
  • Publication number: 20130129750
    Abstract: The application discloses PERLECAN as a new biomarker for renal dysfunction; methods for predicting, diagnosing, prognosticating and/or monitoring said dysfunction based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods.
    Type: Application
    Filed: August 5, 2011
    Publication date: May 23, 2013
    Applicant: PRONOTA N.V.
    Inventors: Koen Kas, Griet Vanpoucke, Piet Moerman
  • Publication number: 20130116151
    Abstract: The application discloses a new tool for predicting, diagnosing and prognosing hypertensive disorders of pregnancy and particularly preeclampsia; methods for the diagnosis, prediction, prognosis and/or monitoring said disorders; and kits and devices for measuring said biomarker and/or performing said methods.
    Type: Application
    Filed: July 8, 2011
    Publication date: May 9, 2013
    Applicant: PRONOTA N.V.
    Inventor: Koen Kas
  • Publication number: 20130045889
    Abstract: The application discloses new biomarkers for hypertensive disorders of pregnancy and particularly preeclampsia; methods for the diagnosis, prediction, prognosis and/or monitoring said disorders based on measuring said biomarkers; and kits and devices for measuring said biomarker and/or performing said methods.
    Type: Application
    Filed: April 13, 2011
    Publication date: February 21, 2013
    Applicant: PRONOTA N.V.
    Inventor: Koen Kas
  • Publication number: 20130040881
    Abstract: The application discloses LTBP2 as a new biomarker for renal dysfunction; methods for predicting, diagnosing, prognosticating and/or monitoring said dysfunction based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods. LTBP2 is also involved in glomerular filtration rate, dyspnea, acute heart failure, left ventricular hypertrophy, cardiac fibrosis, preeclampsia, pregnancy- associated proteinuria.
    Type: Application
    Filed: March 25, 2011
    Publication date: February 14, 2013
    Applicant: Pronota N.V.
    Inventor: Koen Kas
  • Patent number: 8343932
    Abstract: The invention relates to the identification of a naturally occurring internal proteolytic cleavage site in the ApoA1 protein, which leads to inactivation of the mature protein. Specific modification of this cleavage site leads to a stabilised ApoA1 protein, which is beneficial for the reverse cholesterol transport. The invention therefore encompasses pharmaceutical compositions comprising a recombinant stabilised variant ApoA1 protein or rHDL particles comprising such a protein, for use in the treatment of patients having reduced HDL or hampered reverse cholesterol transport.
    Type: Grant
    Filed: October 17, 2008
    Date of Patent: January 1, 2013
    Assignee: Pronota N.V.
    Inventors: Sven Eyckerman, Koen Kas, Christine Labeur
  • Publication number: 20120237962
    Abstract: The application discloses MCAM as a new biomarker for fluid homeostatic imbalance; methods for predicting, diagnosing, prognosticating and/or monitoring fluid homeostatic imbalance based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods.
    Type: Application
    Filed: October 21, 2010
    Publication date: September 20, 2012
    Applicant: Pronota N.V.
    Inventor: Koen Kas
  • Publication number: 20120220493
    Abstract: The application discloses MCAM as a new biomarker for acute heart failure; methods for predicting, diagnosing, prognosticating and/or monitoring acute heart failure based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods.
    Type: Application
    Filed: October 21, 2010
    Publication date: August 30, 2012
    Applicant: Pronota N.V.
    Inventor: Koen Kas
  • Publication number: 20120034240
    Abstract: The application discloses PERLECAN as a new biomarker for renal dysfunction; methods for predicting, diagnosing, prognosticating and/or monitoring said dysfunction based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods.
    Type: Application
    Filed: August 5, 2011
    Publication date: February 9, 2012
    Applicant: Pronota N.V.
    Inventors: Koen Kas, Griet Vanpoucke, Piet Moerman
  • Publication number: 20110275536
    Abstract: The application discloses Quiescin Q6 as a new biomarker for acute heart failure; methods for predicting, diagnosing and/or prognosticating acute heart failure based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods.
    Type: Application
    Filed: January 28, 2010
    Publication date: November 10, 2011
    Applicant: Pronota N.V.
    Inventor: Koen Kas
  • Publication number: 20110256169
    Abstract: The invention provides novel fragments of proBNP and NTproBNP, particularly useful in prognosing or diagnosing acute heart failure, chronic heart failure or sepsis.
    Type: Application
    Filed: May 14, 2009
    Publication date: October 20, 2011
    Applicant: Pronota N.V.
    Inventors: Koen Kas, Robin Tuytten, Koen De Cremer, Griet Vanpoucke
  • Publication number: 20110251094
    Abstract: The application discloses new biomarkers for hypertensive disorders of pregnancy and particularly preeclampsia; methods for the diagnosis, prediction, prognosis and/or monitoring said disorders based on measuring said biomarkers; and kits and devices for measuring said biomarker and/or performing said methods.
    Type: Application
    Filed: April 13, 2011
    Publication date: October 13, 2011
    Applicant: Pronota N.V.
    Inventor: Koen Kas
  • Publication number: 20110237513
    Abstract: The application discloses LTBP2 as a new biomarker for renal dysfunction; methods for predicting, diagnosing, prognosticating and/or monitoring said dysfunction based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods.
    Type: Application
    Filed: March 25, 2011
    Publication date: September 29, 2011
    Applicant: Pronota N.V.
    Inventor: Koen Kas
  • Publication number: 20110059858
    Abstract: The present invention provides kits and methods for the diagnosis, prognosis and prediction of sepsis in a subject using the expression level of the TREML-1 biomarker as an indication of the condition of the patient, alone or in combination with further sepsis markers.
    Type: Application
    Filed: May 19, 2009
    Publication date: March 10, 2011
    Applicant: Pronota N.V.
    Inventors: Koen Kas, Griet Vanpoucke
  • Publication number: 20100311114
    Abstract: The invention mainly concerns methods and systems for the preparation of biological samples for proteome analysis, N-terminal or C-terminal peptides of proteins are enriched using exopeptidase.
    Type: Application
    Filed: October 17, 2008
    Publication date: December 9, 2010
    Applicant: Pronota N.V.
    Inventors: Sven Eyckerman, Koen Kas
  • Publication number: 20100298152
    Abstract: The present invention is a method for measuring the amount of at least one molecule in a biological sample, the method comprising a) combining the sample, or a derivative thereof, with one or more aptamers and allowing one or more molecules in the sample to bind to the aptamer(s); b) separating bound from unbound molecules; and c) quantifying the molecule(s) bound to the or each aptamer, wherein quantification of the bound molecule(s) is carried out by sequencing at least part of the or each aptamer. Uses of and products derived from the method are also contemplated.
    Type: Application
    Filed: October 10, 2008
    Publication date: November 25, 2010
    Applicant: PRONOTA NV
    Inventors: Clive Gavin Brown, Koen Kas, Sven Agnes Jan Eyckerman
  • Publication number: 20100292131
    Abstract: The present invention provides kits and methods for the diagnosis, prognosis and prediction of sepsis in a subject or for the differentiation between sepsis and SIRS in a subject, the method comprising(a) measuring the level of pro-hepcidin (pro-HEPC) in a biological sample taken from said subject, (b) measuring the level of at least one further biomarker selected from the group consisting of soluble TNF-receptor 2 (sTNFR2), Pentraxin-3 (PTX-3), Macrophage Colony-Stimulating Factor (MCSF), pro-Brain Natriuretic Protein (pro-BNP), one or more members of the Histone protein family, Procalcitonin (PCT) and c-Reactive Protein (CRP) in a biological sample from said subject, (c) using said measurements obtained in steps (a) and (b) to create a profile for said biomarkers and (d) comparing said profile with a reference biomarker profile obtained form a patient having SIRS or from a healthy subject.
    Type: Application
    Filed: November 12, 2008
    Publication date: November 18, 2010
    Inventors: Koen Kas, Griet Vanpoucke, Sven Degroeve, Kathleen Huijben
  • Publication number: 20100222276
    Abstract: The invention relates to the identification of a naturally occurring internal proteolytic cleavage site in the ApoA1 protein, which leads to inactivation of the mature protein. Specific modification of this cleavage site leads to a stabilised ApoA1 protein, which is beneficial for the reverse cholesterol transport. The invention therefore encompasses pharmaceutical compositions comprising a recombinant stabilised variant ApoA1 protein or rHDL particles comprising such a protein, for use in the treatment of patients having reduced HDL or hampered reverse cholesterol transport.
    Type: Application
    Filed: October 17, 2008
    Publication date: September 2, 2010
    Applicant: Pronota N.V.
    Inventors: Sven Eyckerman, Koen Kas, Christine Labeur